• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

E-194 A randomized double-blind placebo-controlled trial of prophylactic antidepressant medication for the prevention of depression post aneurysmal subarachnoid hemorrhage
ConclusionsThe initial results of this ongoing study illustrate the feasibility and challenges of mental health screening and prophylactic randomized treatment in the acute care setting for post-SAH patients. Recruitment has been a challenge in this patient population. Here we describe the trends we see in outcomes at 12-months compared to baseline. These trends suggest that despite clinical improvement there may be an increase in depression and anxiety development one-year post-aSAH.Disclosures J. Keen: None. D. Lim: None. K. Prijoles: None. H. Haughn: None. C. Galang: None. A. Duboysky: None. E. Byun: None. K. Carroll: N...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Keen, J., Lim, D., Prijoles, K., Haughn, H., Galang, C., Duboysky, A., Byun, E., Carroll, K., Kelly, C., Federico, E., Gonzalez, A., Levitt, M., Kim, L. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

The ms-smart trial in secondary progressive ms - current update
MS-SMART is an ongoing multicentre, multi-arm, double blind, placebo-controlled phase IIb randomised controlled trial to establish whether putative neuroprotective drugs (fluoxetine,riluzole,amiloride or placebo) can slow down the progression of brain volume loss in secondary progressive multiple sclerosis (SPMS) over 96 weeks using MRI-derived Percentage Brain Volume Change (PBVC) as the primary outcome. 360 patients have been screened so far, 328 (92%) consented and 272 randomized (65% of the total UK cohort–440). Patients will have outcome-data collected after 0,24,48 and 96 weeks. The trial is using a range of co...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Connick, P., Giovannoni, G., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., Plantone, D. Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

The ms-smart trial in secondary progressive multiple sclerosis: a multi-arm, multi-centre trial of neuroprotection
There is currently no treatment for secondary progressive multiple sclerosis (SPMS) which determines the majority of disability in multiple sclerosis. The MS-SMART trial is a multi-arm, multi-centre, phase 2 randomised trial for patients with SPMS. A total of 440 patients with progressing SPMS will be recruited in England and Scotland and randomised to one of 4 blinded arms: amiloride 5mg bd, riluzole 50mg bd, fluoxetine 20mg bd or placebo. These agents have been chosen after an extensive systematic review which has suggested putative neuroprotective properties. Patients will be followed up for 96 weeks with outcome data c...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Giovannoni, G., Wheeler-Kingshott, C., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., for the MS-SMART trialists Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) Thur 21, Parallel session 5: Therapeutics Source Type: research